{
    "eid": "2-s2.0-85007017321",
    "title": "Advances in cholangiocarcinoma research: Report from the third cholangiocarcinoma foundation annual conference",
    "cover-date": "2016-01-01",
    "subject-areas": [
        {
            "$": "Gastroenterology",
            "@code": "2715"
        },
        {
            "$": "Oncology",
            "@code": "2730"
        }
    ],
    "keywords": [],
    "authors": [
        "Ghassan K. Abou-Alfa"
    ],
    "citedby-count": 16,
    "ref-count": 40,
    "ref-list": [
        "Intrahepatic cholangiocarcinoma: An international multi-institutional analysis of prognostic factors and lymph node assessment",
        "The landscape of targeted therapies for cholangiocarcinoma: Current status and emerging targets",
        "2016 Annual Conference",
        "Neoadjuvant therapy and liver transplantation for hilar cholangiocarcinoma: Is pretreatment pathological confirmation of diagnosis necessary?",
        "Adjuvant therapy in the treatment of biliary tract cancer: A systematic review and meta-analysis",
        "Mutation profiling in cholangiocarcinoma: Prognostic and therapeutic implications",
        "Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas",
        "Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers",
        "Multi-institutional phase II study of high-dose hypofractionated proton beam therapy in patients with localized, unresectable hepatocellular carcinoma and intrahepatic cholangiocarcinoma",
        "SWOG S0809: A phase II intergroup trial of adjuvant capecitabine and gemcitabine followed by radiotherapy and concurrent capecitabine in extrahepatic cholangiocarcinoma and gallbladder carcinoma",
        "Comprehensive genomic profiling of extrahepatic cholangiocarcinoma reveals a long tail of therapeutic targets",
        "J Clin Oncol",
        "Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer",
        "Prognosis and clinicopathologic features of patients with advanced stage isocitrate dehydrogenase (IDH) mutant and IDH wild-type intrahepatic cholangiocarcinoma",
        "Cisplatin and gemcitabine for advanced biliary tract cancer: A meta-analysis of two randomised trials",
        "Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: A phase 2 study",
        "Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): A randomised, open-label, non-comparative phase 2 trial",
        "J Clin Oncol",
        "Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: A multicentre, open-label, randomised, phase 3 study",
        "Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti-BIL study)",
        "Genetics of biliary tract cancers and emerging targeted therapies",
        "New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing",
        "Molecular Targets and Cancer Therapeutics",
        "J Clin Oncol",
        "Eur J Cancer",
        "Genomic spectra of biliary tract cancer",
        "Roles of liver fluke infection as risk factor for cholangiocarcinoma",
        "Immunotherapy in hepatocellular carcinoma: Primed to make a difference?",
        "A hippo and fibroblast growth factor receptor autocrine pathway in cholangiocarcinoma",
        "Platelet-derived growth factor primes cancer-associated fibroblasts for apoptosis",
        "Cholangiocarcinomas can originate from hepatocytes in mice",
        "Intrahepatic cholangiocarcinoma can arise from Notch-mediated conversion of hepatocytes",
        "Cell lineage tracing reveals a biliary origin of intrahepatic cholangiocarcinoma",
        "Mutant IDH inhibits HNF-4\u03b1 to block hepatocyte differentiation and promote biliary cancer",
        "Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma",
        "Suppression of hepatocyte proliferation by hepatocyte nuclear factor 4\u03b1 in adult mice",
        "WNT signaling drives cholangiocarcinoma growth and can be pharmacologically inhibited",
        "Hepatocyte nuclear factor 4 alpha deletion promotes diethylnitrosamine-induced hepatocellular carcinoma in rodents",
        "Hepatocyte-specific deletion of hepatocyte nuclear factor-4\u03b1in adult mice results in increased hepatocyte proliferation",
        "Dysregulation of Wnt/\u03b2-catenin signaling in gastrointestinal cancers"
    ],
    "affiliation": [
        {
            "affiliation-city": "Seattle",
            "affilname": "Fred Hutchinson Cancer Center",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Copenhagen",
            "affilname": "Biotech Research &amp; Innovation Centre",
            "affiliation-country": "Denmark"
        },
        {
            "affiliation-city": "Boston",
            "affilname": "Massachusetts General Hospital",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Bangkok",
            "affilname": "Chulalongkorn University",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Edinburgh",
            "affilname": "The University of Edinburgh",
            "affiliation-country": "United Kingdom"
        },
        {
            "affiliation-city": "Dallas",
            "affilname": "UT Southwestern Medical Center",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Ann Arbor",
            "affilname": "University of Michigan, Ann Arbor",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "San Francisco",
            "affilname": "University of California, San Francisco",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Cambridge",
            "affilname": "Massachusetts Institute of Technology",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Boston",
            "affilname": "Brigham and Women's Hospital",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Houston",
            "affilname": "The University of Texas MD Anderson Cancer Center",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "St. Louis",
            "affilname": "Washington University in St. Louis",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "New York",
            "affilname": "Memorial Sloan-Kettering Cancer Center",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "New York",
            "affilname": "Weill Cornell Medicine",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Philadelphia",
            "affilname": "University of Pennsylvania",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Rochester",
            "affilname": "Mayo Clinic",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "New York",
            "affilname": "The Mount Sinai Hospital",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Manchester",
            "affilname": "The University of Manchester",
            "affiliation-country": "United Kingdom"
        },
        {
            "affiliation-city": "Salt Lake City",
            "affilname": "Cholangiocarcinoma Foundation",
            "affiliation-country": "United States"
        }
    ],
    "funding": []
}